--- title: "Pre-market trend | ORBUSNEICH (6929.HK) 5/11 Medical devices warming up, are low-level bullish signals emerging?" type: "News" locale: "en" url: "https://longbridge.com/en/news/285906982.md" description: "Yesterday's closing price for ORBUSNEICH was HKD 4.5, with a trading volume of approximately HKD 6.85 million, which is considered a normal level of activity among small and mid-cap medical device stocks. The MACD daily line formed a golden cross above the zero axis, a signal typically viewed as a technical confirmation of a shift in the short-term trend from consolidation to a bullish bias, indicating that buying power is gathering in phases. From recent trends, the stock price has gradually stabilized and rebounded from previous lows, with short-term moving averages beginning to turn upward. On the news front, the medical device sector has recently received multiple policy benefits. The domestic medical equipment upgrade policy continues to advance, coupled with the logic of going overseas, leading to increased attention on Hong Kong-listed medical supplies. Major stocks in the pharmaceutical sector, such as Innovent Biologics and CanSino Biologics, maintain high trading levels, indicating that capital enthusiasm for the healthcare sector remains strong. ORBUSNEICH focuses on the field of coronary intervention devices, and under the dual drive of domestic substitution and overseas expansion, the industry's prosperity is expected to continue to rise. From a technical perspective, the area around HKD 4.5 is an important consolidation platform for ORBUSNEICH recently, and the appearance of the MACD golden cross suggests that the balance between bulls and bears is tilting towards the bulls. Short-term moving averages have started to turn upward from a flat position; if there is a subsequent volume breakout above recent highs, the upward space is expected to further open up. However, the current trading volume of HKD 6.85 million is still relatively low, and signs of large capital entering the market are not yet apparent. In terms of risk, small-cap medical device stocks have limited liquidity, and intraday volatility may be significant, while industry policies such as centralized procurement and price reductions may impact the company's profitability. The technical signals are somewhat positive, but further confirmation of increased volume is needed" datetime: "2026-05-12T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285906982.md) - [en](https://longbridge.com/en/news/285906982.md) - [zh-HK](https://longbridge.com/zh-HK/news/285906982.md) --- # Pre-market trend | ORBUSNEICH (6929.HK) 5/11 Medical devices warming up, are low-level bullish signals emerging? Yesterday's closing price for ORBUSNEICH was HKD 4.5, with a trading volume of approximately HKD 6.85 million, which is considered a normal level of activity among small and mid-cap medical device stocks. The MACD daily line formed a golden cross above the zero axis, a signal typically viewed as a technical confirmation of a short-term trend shifting from consolidation to a bullish bias, indicating that buying pressure is accumulating. From recent trends, the stock price has gradually stabilized and rebounded from previous lows, with short-term moving averages beginning to turn upward. On the news front, the medical device sector has recently received multiple policy benefits. The domestic medical equipment upgrade policy continues to advance, coupled with the logic of going overseas, leading to increased attention on Hong Kong-listed medical supplies. Major stocks in the pharmaceutical sector, such as Innovent Biologics and CanSino Biologics, maintain high trading levels, indicating that investor enthusiasm for the healthcare sector remains strong. ORBUSNEICH focuses on coronary intervention devices, and with the dual drivers of domestic substitution and overseas expansion, the industry's prosperity is expected to continue to rise. From a technical perspective, HKD 4.5 is an important consolidation platform for ORBUSNEICH recently. The appearance of the MACD golden cross suggests that the balance between bulls and bears is tilting towards the bulls. Short-term moving averages have begun to turn upward from a flat position; if there is a subsequent volume breakout above recent highs, the upward space is expected to further open up. However, the current trading volume of HKD 6.85 million is still relatively low, and signs of large capital entering the market are not yet evident. In terms of risks, small-cap medical device stocks have limited liquidity, and intraday volatility may be significant. Additionally, industry policies such as centralized procurement and price reductions may impact the company's profitability. The technical signals are somewhat positive, but further confirmation through increased volume is needed. _This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [06929.HK](https://longbridge.com/en/quote/06929.HK.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [562600.CN](https://longbridge.com/en/quote/562600.CN.md) - [517110.CN](https://longbridge.com/en/quote/517110.CN.md) - [159898.CN](https://longbridge.com/en/quote/159898.CN.md) - [159883.CN](https://longbridge.com/en/quote/159883.CN.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) ## Related News & Research - [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md) - [Shanghai Henlius wins Australia clearance to start Phase 1 HLX3902 cancer trial](https://longbridge.com/en/news/287190785.md) - [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md) - [Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium](https://longbridge.com/en/news/286258287.md) - [SSY Group wins China NMPA approval for emedastine difumarate eye drops 0.05%](https://longbridge.com/en/news/287187916.md)